

Rudolf A De Boer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4682066/publications.pdf>

Version: 2024-02-01

368
papers

35,907
citations

5267

83
h-index

4342

173
g-index

378
all docs

378
docs citations

378
times ranked

29864
citing authors

#	ARTICLE	IF	CITATIONS
1	Rationale and design of the PHospholamban RElated CARDiomyopathy intervention STudy (i-PHORECAST). Netherlands Heart Journal, 2022, 30, 84-95.	0.8	10
2	Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF. Cardiovascular Research, 2022, 118, 1964-1977.	3.8	10
3	Management of cardiac fibrosis is the largest unmet medical need in heart failure. Cardiovascular Research, 2022, 118, e20-e22.	3.8	23
4	Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF- β signalling. Angiogenesis, 2022, 25, 99-112.	7.2	8
5	Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers. European Heart Journal Cardiovascular Imaging, 2022, 23, 1492-1501.	1.2	6
6	Reverse cardio-oncology: Exploring the effects of cardiovascular disease on cancer pathogenesis. Journal of Molecular and Cellular Cardiology, 2022, 163, 1-8.	1.9	32
7	Cardiovascular disease related circulating biomarkers and cancer incidence and mortality: is there an association?. Cardiovascular Research, 2022, 118, 2317-2328.	3.8	15
8	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, 2022, 145, 158-169.	1.6	18
9	Pectins from various sources inhibit galectin-3-related cardiac fibrosis. Current Research in Translational Medicine, 2022, 70, 103321.	1.8	2
10	Sex-specific aspects of phospholamban cardiomyopathy: The importance and prognostic value of low-voltage electrocardiograms. Heart Rhythm, 2022, 19, 427-434.	0.7	8
11	The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. European Heart Journal, 2022, 43, 367-376.	2.2	13
12	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. European Journal of Heart Failure, 2022, 24, 308-320.	7.1	9
13	Sex disparities in the effect of statins on lipid parameters. Medicine (United States), 2022, 101, e28394.	1.0	7
14	SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. Journal of Lipid and Atherosclerosis, 2022, 11, 1.	3.5	25
15	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2022, 24, 406-420.	7.1	22
16	High selenium levels associate with reduced risk of mortality and new-onset heart failure: data from <sc>PREVEND</sc>. European Journal of Heart Failure, 2022, 24, 299-307.	7.1	19
17	Relative fat mass, a new index of adiposity, is strongly associated with incident heart failure: data from PREVEND. Scientific Reports, 2022, 12, 147.	3.3	21
18	Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: <sc>EAT</sc> your heart outâ€¦!. European Journal of Heart Failure, 2022, 24, 362-364.	7.1	0

#	ARTICLE	IF	CITATIONS
19	Immune checkpoint inhibitor-associated myocarditis. Netherlands Heart Journal, 2022, 30, 295-301.	0.8	8
20	Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?. European Journal of Heart Failure, 2022, 24, 287-298.	7.1	16
21	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
22	Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. European Heart Journal, 2022, 43, 1955-1969.	2.2	90
23	Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nature Reviews Nephrology, 2022, 18, 294-306.	9.6	64
24	Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation. International Journal of Molecular Sciences, 2022, 23, 2427.	4.1	5
25	Female rats are less prone to clinical heart failure than male rats in a juvenile rat model of right ventricular pressure load. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 322, H994-H1002.	3.2	5
26	Cardiac remodelling—Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 927-943.	7.1	29
27	Association of Cardiometabolic Disease With Cancer in the Community. JACC: CardioOncology, 2022, 4, 69-81.	4.0	10
28	Sex differences in associations of comorbidities with incident cardiovascular disease: focus on absolute risk. European Heart Journal Open, 2022, 2, .	2.3	2
29	Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009238.	3.9	40
30	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867.	2.2	14
31	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.	1.6	53
32	The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Cardiologia Croatica, 2022, 17, 27-43.	0.0	1
33	Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer. Nature Reviews Cardiology, 2022, 19, 414-425.	13.7	23
34	Aging and HFpEF: Are we running out of time?. Journal of Molecular and Cellular Cardiology, 2022, 168, 33-34.	1.9	1
35	Circulating levels and prognostic cutoffs of sST2, hsTnT, and NT-proBNP in women vs. men with chronic heart failure. ESC Heart Failure, 2022, 9, 2084-2095.	3.1	15
36	MO504: Urinary Albumin Excretion and Cancer Risk. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0

#	ARTICLE	IF	CITATIONS
37	Urinary potassium excretion and mortality risk in community-dwelling individuals with and without obesity. American Journal of Clinical Nutrition, 2022, 116, 741-749.	4.7	1
38	Distinct pathophysiological pathways in women and men with heart failure. European Journal of Heart Failure, 2022, 24, 1532-1544.	7.1	10
39	Value of genetic testing in the diagnosis and risk stratification of arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2022, 19, 1659-1665.	0.7	6
40	Blood-based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta-analysis. ESC Heart Failure, 2022, 9, 3418-3434.	3.1	6
41	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovascular Research, 2021, 117, 2108-2124.	3.8	108
42	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 2021, 117, 2228-2236.	3.8	8
43	Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction. European Journal of Preventive Cardiology, 2021, 28, 957-965.	1.8	13
44	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2021, 143, 298-309.	1.6	193
45	Being in Two Minds – The Challenge of Heart Failure with Preserved Ejection Fraction Diagnosis with a Single Biomarker. Clinical Chemistry, 2021, 67, 46-49.	3.2	1
46	Early Mechanical Alterations in Phospholamban Mutation Carriers. JACC: Cardiovascular Imaging, 2021, 14, 885-896.	5.3	11
47	Fighting HFpEF in women: taking aim at belly fat. European Heart Journal, 2021, 42, 1606-1608.	2.2	8
48	Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients. Surgery for Obesity and Related Diseases, 2021, 17, 64-71.	1.2	1
49	Plasma creatine and incident type 2 diabetes in a general population-based cohort: The PREVEND study. Clinical Endocrinology, 2021, 94, 563-574.	2.4	11
50	Association of beta-hydroxybutyrate with development of heart failure: Sex differences in a Dutch population cohort. European Journal of Clinical Investigation, 2021, 51, e13468.	3.4	25
51	Evaluation of 2 Existing Diagnostic Scores for Heart Failure With Preserved Ejection Fraction Against a Comprehensively Phenotyped Cohort. Circulation, 2021, 143, 289-291.	1.6	30
52	Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. Circulation: Heart Failure, 2021, 14, e007684.	3.9	87
53	Volume Load-Induced Right Ventricular Failure in Rats Is Not Associated With Myocardial Fibrosis. Frontiers in Physiology, 2021, 12, 557514.	2.8	3
54	BIO FOR CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants – design and status. Netherlands Heart Journal, 2021, 29, 318-329.	0.8	7

#	ARTICLE	IF	CITATIONS
55	What You Did Not Know About Cardiac Ca ²⁺ Handling. <i>Circulation</i> , 2021, 143, 466-469.	1.6	2
56	Relationship between body mass index, cardiovascular biomarkers and incident heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 396-402.	7.1	17
57	Cardiovascular Risk Factors Are Associated With Future Cancer. <i>JACC: CardioOncology</i> , 2021, 3, 48-58.	4.0	83
58	The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2955.	4.1	9
59	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 527-540.	7.1	37
60	The <sc>Heart Failure Association Atlas</sc>: <sc>Heart Failure Epidemiology and Management Statistics</sc> 2019. <i>European Journal of Heart Failure</i> , 2021, 23, 906-914.	7.1	130
61	Age dependent associations of risk factors with heart failure: pooled population based cohort study. <i>BMJ</i> , The, 2021, 372, n461.	6.0	83
62	ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca ²⁺ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKII β . <i>International Journal of Molecular Sciences</i> , 2021, 22, 4427.	4.1	9
63	Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1660-1669.	2.8	111
64	The emerging plasma biomarker Dickkopf-3 (DKK3) and its association with renal and cardiovascular disease in the general population. <i>Scientific Reports</i> , 2021, 11, 8642.	3.3	15
65	Impaired High-Density Lipoprotein Function in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e019123.	3.7	9
66	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. <i>JACC: Heart Failure</i> , 2021, 9, 254-264.	4.1	75
67	Diagnostic recommendations and phenotyping for heart failure with preserved ejection fraction: knowing more and understanding less?. <i>European Journal of Heart Failure</i> , 2021, 23, 964-972.	7.1	5
68	Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association. <i>Circulation Research</i> , 2021, 129, e21-e34.	4.5	37
69	Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction. <i>European Heart Journal</i> , 2021, 42, 2842-2850.	2.2	54
70	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <sc>DELIVER</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1217-1225.	7.1	195
71	Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2458-2466.	3.1	13
72	A new classification of cardio-oncology syndromes. <i>Cardio-Oncology</i> , 2021, 7, 24.	1.7	27

#	ARTICLE	IF	CITATIONS
73	Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction. Netherlands Heart Journal, 2021, 29, 383-393.	0.8	5
74	Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes. Cardiovascular Diabetology, 2021, 20, 123.	6.8	9
75	Usefulness of High-Sensitivity Cardiac Troponin T to Predict Long-Term Outcome in Patients with Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2021, 152, 120-124.	1.6	8
76	Identification of sex-specific biomarkers predicting new-onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520.	3.1	11
77	The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise. Pflugers Archiv European Journal of Physiology, 2021, 473, 1301-1313.	2.8	10
78	Dynamic loading of human engineered heart tissue enhances contractile function and drives a desmosome-linked disease phenotype. Science Translational Medicine, 2021, 13, .	12.4	48
79	Evaluation of renal cancer progression in a mouse model of heart failure. Cancer Communications, 2021, 41, 796-799.	9.2	9
80	From Studying Heart Disease and Cancer Simultaneously to Reverse Cardio-Oncology. Circulation, 2021, 144, 93-95.	1.6	16
81	The "Peptide for Life"™ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. European Journal of Heart Failure, 2021, 23, 1432-1436.	7.1	10
82	Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy. Nature Communications, 2021, 12, 5180.	12.8	24
83	Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. European Heart Journal, 2021, 42, 4420-4430.	2.2	65
84	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
85	Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines Initiative. Current Medical Research and Opinion, 2021, , 1-1.	1.9	1
86	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<scp>HFA</scp>), European Society of Cardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2021, 23, 1610-1632.	7.1	69
87	Kidney Function in Patients With Neuromuscular Disease: Creatinine Versus Cystatin C. Frontiers in Neurology, 2021, 12, 688246.	2.4	1
88	Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e008532.	3.9	17
89	NT-proBNP for Risk Prediction in Heart Failure. JACC: Heart Failure, 2021, 9, 653-663.	4.1	20
90	Ketone bodies for the failing heart: fuels that can fix the engine?. Trends in Endocrinology and Metabolism, 2021, 32, 814-826.	7.1	26

#	ARTICLE	IF	CITATIONS
91	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. <i>Nature Genetics</i> , 2021, 53, 128-134.	21.4	155
92	Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-year Prospective Cohort Study. <i>Transplantation</i> , 2021, 105, 1106-1115.	1.0	8
93	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021, 44, 586-594.	8.6	50
94	Proenkephalin and the risk of new-onset heart failure: data from prevention of renal and vascular end-stage disease. <i>Clinical Cardiology</i> , 2021, , .	1.8	4
95	Selenoprotein DIO2 Is a Regulator of Mitochondrial Function, Morphology and UPRmt in Human Cardiomyocytes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11906.	4.1	13
96	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008837.	3.9	21
97	Exploring the Correlation Between Fibrosis Biomarkers and Clinical Disease Severity in PLN p.Arg14del Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 802998.	2.4	6
98	Atrial fibrillation detected at screening is not a benign condition: outcomes in screen-detected versus clinically detected atrial fibrillation. Results from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study. <i>Open Heart</i> , 2021, 8, e001786.	2.3	2
99	Established Tumour Biomarkers Predict Cardiovascular Events and Mortality in the General Population. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 753885.	2.4	10
100	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. <i>Molecular Psychiatry</i> , 2020, 25, 2392-2409.	7.9	83
101	Current understanding of fibrosis in genetic cardiomyopathies. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 353-361.	4.9	45
102	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020, 109, 331-338.	3.3	28
103	Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?. <i>Cardiovascular Diabetology</i> , 2020, 19, 5.	6.8	29
104	Mitochondrial therapy for doxorubicin cardiomyopathy: nuclear factor- κ B to the rescue?. <i>Cardiovascular Research</i> , 2020, 116, 1092-1094.	3.8	3
105	Improve Management of acute heart failure with ProcAICiTonin in EUrope: results of the randomized clinical trial IMPACT- α -EU Biomarkers in Cardiology (BIC) 18. <i>European Journal of Heart Failure</i> , 2020, 22, 267-275.	7.1	20
106	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	7.1	131
107	Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study. <i>Nutrients</i> , 2020, 12, 2711.	4.1	7
108	Transforming heart failure and cardio-oncology care during COVID-19. <i>ESC Heart Failure</i> , 2020, 7, 3278-3280.	3.1	1

#	ARTICLE	IF	CITATIONS
109	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€œOncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€œOncology Council of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2020, 22, 1966-1983.	7.1	184
110	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation, 2020, 142, 1040-1054.	1.6	128
111	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1820-1834.	3.8	51
112	Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals. Nature Genetics, 2020, 52, 1314-1332.	21.4	91
113	Left ventricular dysfunction in heart failure with preserved ejection fractionâ€”molecular mechanisms and impact on right ventricular function. Cardiovascular Diagnosis and Therapy, 2020, 10, 1541-1560.	1.7	14
114	Unraveling the Genotypeâ€œPhenotype Relationship in Hypertrophic Cardiomyopathy: Obesityâ€œRelated Cardiac Defects as a Major Disease Modifier. Journal of the American Heart Association, 2020, 9, e018641.	3.7	16
115	Cellular senescence impairs the reversibility of pulmonary arterial hypertension. Science Translational Medicine, 2020, 12, .	12.4	74
116	Progress in heart failure management in the Netherlands and beyond: long-term commitment to deliver high-quality research and patient care. Netherlands Heart Journal, 2020, 28, 31-38.	0.8	5
117	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	7.1	92
118	Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Metaâ€œAnalysis. Journal of the American Heart Association, 2020, 9, e016309.	3.7	23
119	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 142, 1623-1632.	1.6	51
120	Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident Heartâ€œFailure. Journal of the American College of Cardiology, 2020, 76, 1455-1465.	2.8	54
121	A combined bioinformatics, experimental and clinical approach to identify novel cardiacâ€œspecific heart failure biomarkers: is Dickkopf â€3 (DKK3) a possible candidate?. European Journal of Heart Failure, 2020, 22, 2065-2074.	7.1	10
122	Strength of patient cohorts and biobanks for cardiomyopathy research. Netherlands Heart Journal, 2020, 28, 50-56.	0.8	1
123	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 2020, 41, 3402-3418.	2.2	90
124	Genetic Determinants of Electrocardiographic P-Wave Duration and Relation to Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2020, 13, 387-395.	3.6	16
125	P0055GALECTIN-3 STRONGLY ASSOCIATES WITH RENAL FUNCTION, CARDIOMYOPATHY AND FIBROSIS IN PATIENTS WITH FABRY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
126	Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study. Nephrology Dialysis Transplantation, 2020, 36, 1828-1836.	0.7	6

#	ARTICLE	IF	CITATIONS
127	Tumour biomarkers: association with heart failure outcomes. Journal of Internal Medicine, 2020, 288, 207-218.	6.0	27
128	Implementing the new European Regulations on medical devicesâ€”clinical responsibilities for evidence-based practice: a report from the Regulatory Affairs Committee of the European Society of Cardiology. European Heart Journal, 2020, 41, 2589-2596.	2.2	37
129	therapies: a position statement and new risk assessment tools from the <sc>C</sc>ardioâ€œ<sc>O</sc>ncology <sc>S</sc>udy <sc>G</sc>roup of the <sc>H</sc>eart <sc>F</sc>ailure <sc>A</sc>ssociation of the <sc>E</sc>uropean <sc>S</sc>ociety of <sc>C</sc>ardiology in collaboration with the <sc>I</sc>nternational <sc>C</sc>ardioâ€œ<sc>O</sc>ncology <sc>S</sc>ociety. European Journal of Heart Failure, 2020,	7.1	364
130	Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction. Cardiovascular Drugs and Therapy, 2020, 35, 953-963.	2.6	4
131	Surviving the first <sc>COVID</sc>â€”19 wave and learning lessons for the second. European Journal of Heart Failure, 2020, 22, 975-977.	7.1	12
132	High-Sensitivity Troponin-T and Cardiovascular Outcomes in the Community: Differences Between Women and Men. Mayo Clinic Proceedings, 2020, 95, 1158-1168.	3.0	10
133	Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart. Journal of Internal Medicine, 2020, 288, 491-506.	6.0	20
134	Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues. Current Oncology Reports, 2020, 22, 67.	4.0	20
135	The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy. Scientific Reports, 2020, 10, 9819.	3.3	38
136	Effects of Sodiumâ€”Glucose Co-transporter 2 Inhibition with Empagliflozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. Cardiovascular Drugs and Therapy, 2020, 34, 311-321.	2.6	10
137	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	7.4	340
138	Sexâ€”related differences in contemporary biomarkers for heart failure: a review. European Journal of Heart Failure, 2020, 22, 775-788.	7.1	55
139	How to diagnose heart failure with preserved ejection fraction: the HFAâ€”PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 391-412.	7.1	193
140	Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. European Journal of Heart Failure, 2020, 22, 1586-1597.	7.1	16
141	Aortic regurgitation, a forgotten valve disease in hypertrophic cardiomyopathy?. European Journal of Radiology, 2020, 126, 108971.	2.6	0
142	Proactive screening for symptoms: A simple method to improve early detection of unrecognized cardiovascular disease in primary care. Results from the Lifelines Cohort Study. Preventive Medicine, 2020, 138, 106143.	3.4	7
143	Sodiumâ€”glucose coâ€”transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	7.1	100
144	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the <sc>H</sc>eart <sc>F</sc>ailure <sc>A</sc>ssociation of <sc>C</sc>ardiovascular <sc>I</sc>maging (<sc>EACVI</sc>) and the <sc>C</sc>ardioâ€œOncology <sc>C</sc>ouncil of the <sc>E</sc>uropean <sc>S</sc>ociety of <sc>C</sc>ardiology (<sc>ESC</sc>). European Journal of Heart Failure, 2020, 22, 1504-1524.	7.1	234

#	ARTICLE	IF	CITATIONS
145	Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. British Journal of Clinical Pharmacology, 2020, 86, 1346-1356.	2.4	35
146	Troponins and natriuretic peptides to detect cardiotoxicity: useful biomarkers or paradise lost?. European Journal of Heart Failure, 2020, 22, 362-365.	7.1	2
147	Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease. Journal of the American Heart Association, 2020, 9, e013754.	3.7	73
148	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314.	7.1	50
149	Omics phenotyping in heart failure: the next frontier. European Heart Journal, 2020, 41, 3477-3484.	2.2	48
150	Lifestyle components: Self-reported physical activity, nutritional status, sleep quality and incident atrial fibrillation. IJC Heart and Vasculature, 2020, 27, 100492.	1.1	1
151	The association of multimorbidity within cardio-metabolic disease domains with dietary patterns: A cross-sectional study in 129 369 men and women from the Lifelines cohort. PLoS ONE, 2019, 14, e0220368.	2.5	22
152	Cancer and heart disease: associations and relations. European Journal of Heart Failure, 2019, 21, 1515-1525.	7.1	120
153	Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. Heart Failure Reviews, 2019, 24, 915-925.	3.9	39
154	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. European Journal of Heart Failure, 2019, 21, 1561-1570.	7.1	9
155	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. JACC Basic To Translational Science, 2019, 4, 831-840.	4.1	65
156	USE OF THIAZIDE DIURETICS DOES NOT WORSEN DISEASE PROGRESSION IN ADPKD. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
157	Dyssynchronopathy Can be a Manifestation of Heritable Cardiomyopathy. Circulation Genomic and Precision Medicine, 2019, 12, e002528.	3.6	0
158	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	2.2	944
159	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	27.0	4,108
160	Response by Meijers and de Boer to Letters Regarding Article, "Heart Failure Stimulates Tumor Growth by Circulating Factors". Circulation, 2019, 139, 720-721.	1.6	1
161	The vicious cycle of arrhythmia and myocardial fibrosis. European Journal of Heart Failure, 2019, 21, 492-494.	7.1	9
162	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	7.1	182

#	ARTICLE	IF	CITATIONS
163	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 1169-1186.	7.1	490
164	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. <i>European Journal of Heart Failure</i> , 2019, 21, 715-731.	7.1	446
165	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 827-843.	7.1	223
166	10-Year Risk Equations for Incident Heart Failure in the General Population. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2388-2397.	2.8	107
167	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005544.	3.9	23
168	Sodium-glucose cotransporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. <i>European Journal of Heart Failure</i> , 2019, 21, 862-873.	7.1	236
169	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	7.1	224
170	A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	7.1	264
171	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	2.2	195
172	A novel method optimizing the normalization of cardiac parameters in small animal models: the importance of dimensional indexing. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 316, H1552-H1557.	3.2	21
173	P4542 Revisiting the obesity paradox in heart failure: percent body fat as predictor of biomarkers and outcome. <i>European Heart Journal</i> , 2019, 40, .	2.2	1
174	P3434 Galectin-3 identifies healthy subjects at risk of developing (pre-)diastolic dysfunction. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
175	P3515 Gender differences in plasma levels and prognostic value of NT-proBNP in chronic heart failure. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
176	Recent advances in cardio-oncology: a report from the Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019™. <i>ESC Heart Failure</i> , 2019, 6, 1140-1148.	3.1	34
177	Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling. <i>Scientific Reports</i> , 2019, 9, 18765.	3.3	27
178	Distinct molecular signature of phospholamban p.Arg14del arrhythmogenic cardiomyopathy. <i>Cardiovascular Pathology</i> , 2019, 40, 2-6.	1.6	16
179	Discussion forum response to Canepa et al. <i>European Heart Journal</i> , 2019, 40, 705-706.	2.2	1
180	Moving galectin-3 closer to the goal line. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 316, H580-H582.	3.2	2

#	ARTICLE	IF	CITATIONS
181	Assessment of reversibility in pulmonary arterial hypertension and congenital heart disease. Heart, 2019, 105, 276-282.	2.9	37
182	Telemedicine in heart failure“more than nice to have?. Netherlands Heart Journal, 2019, 27, 5-15.	0.8	29
183	Prevalence and cardiac phenotype of patients with a phospholamban mutation. Netherlands Heart Journal, 2019, 27, 64-69.	0.8	52
184	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	2.2	123
185	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 92-100.	1.2	48
186	World Heart Federation Roadmap for Heart Failure. Global Heart, 2019, 14, 197.	2.3	67
187	Common risk factors for heart failure and cancer. Cardiovascular Research, 2019, 115, 844-853.	3.8	175
188	Proenkephalin and risk of developing chronic kidney disease: the Prevention of Renal and Vascular End-stage Disease study. Biomarkers, 2018, 23, 474-482.	1.9	6
189	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. European Journal of Heart Failure, 2018, 20, 879-887.	7.1	138
190	Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. European Journal of Heart Failure, 2018, 20, 910-919.	7.1	225
191	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	7.1	434
192	Novel heart failure biomarkers: why do we fail to exploit their potential?. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 246-263.	6.1	67
193	Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation, 2018, 138, 678-691.	1.6	229
194	Subcutaneous Furosemide in Heart Failure. JACC Basic To Translational Science, 2018, 3, 25-34.	4.1	27
195	N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure. ESC Heart Failure, 2018, 5, 279-287.	3.1	8
196	Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. Circulation: Heart Failure, 2018, 11, e004519.	3.9	147
197	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. Circulation, 2018, 137, 286-297.	1.6	157
198	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. European Journal of Heart Failure, 2018, 20, 260-267.	7.1	30

#	ARTICLE	IF	CITATIONS
199	Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 215.	6.1	186
200	Myocardial oedema and congestive heart failure: one piece of the puzzle? Reply. European Journal of Heart Failure, 2018, 20, 827-828.	7.1	0
201	Heart transplantation in the Netherlands. Netherlands Heart Journal, 2018, 26, 223-224.	0.8	3
202	Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2018, 20, 1081-1099.	7.1	57
203	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	7.1	239
204	Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population. International Journal of Cardiology, 2018, 250, 188-194.	1.7	19
205	Predictors and outcomes of heart failure with mid-range ejection fraction. European Journal of Heart Failure, 2018, 20, 651-659.	7.1	91
206	Galectin-3 in Heart Failure. Heart Failure Clinics, 2018, 14, 75-92.	2.1	86
207	An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 216-227.	7.1	81
208	Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 1615-1633.	7.1	74
209	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology, 2018, 72, 2309-2320.	2.8	126
210	Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes. Journal of the American College of Cardiology, 2018, 72, 3246-3254.	2.8	51
211	Modern-day cardio-oncology: a report from the Heart Failure and World Congress on Acute Heart Failure 2018™. ESC Heart Failure, 2018, 5, 1083-1091.	3.1	23
212	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	2.2	171
213	Association of Low Urinary Sodium Excretion With Increased Risk of Stroke. Mayo Clinic Proceedings, 2018, 93, 1803-1809.	3.0	24
214	Individual variations in cardiovascular-disease-related protein levels are driven by genetics and gut microbiome. Nature Genetics, 2018, 50, 1524-1532.	21.4	97
215	Common and Rare Coding Genetic Variation Underlying the Electrocardiographic PR Interval. Circulation Genomic and Precision Medicine, 2018, 11, e002037.	3.6	19
216	Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population. European Journal of Heart Failure, 2018, 20, 1205-1214.	7.1	60

#	ARTICLE	IF	CITATIONS
217	Prediction of Extensive Myocardial Fibrosis in Nonhigh Risk Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 483-489.	1.6	8
218	High-Sensitivity Troponin and Heart Failure With Preserved Ejection FractionâBalancing <i>P</i> Values With Prior Knowledge and Common SenseâReply. JAMA Cardiology, 2018, 3, 892.	6.1	6
219	Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. Theranostics, 2018, 8, 593-609.	10.0	187
220	Exome-chip meta-analysis identifies novel loci associated with cardiac conduction, including ADAMTS6. Genome Biology, 2018, 19, 87.	8.8	47
221	The Association of Obesity and Cardiometabolic Traits With IncidentÂHFpEF and HFrEF. JACC: Heart Failure, 2018, 6, 701-709.	4.1	254
222	OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. Cardiovascular Research, 2018, 114, 1871-1882.	3.8	38
223	Novel concept to guide systolic heart failure medication by repeated biomarker testingâresults from TIME-CHF in context of predictive, preventive, and personalized medicine. EPMA Journal, 2018, 9, 161-173.	6.1	10
224	Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics, 2018, 8, 4155-4169.	10.0	68
225	Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal, 2018, 39, 2780-2792.	2.2	250
226	HE4 Serum Levels Are Associated with Heart Failure Severity in Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 12-19.	1.7	42
227	The fate of sulfate in chronic heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 312, H415-H421.	3.2	11
228	Meta-Analysis of Soluble Suppression ofÂTumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, 2017, 5, 287-296.	4.1	104
229	Discovery of novel heart rate-associated loci using the Exome Chip. Human Molecular Genetics, 2017, 26, 2346-2363.	2.9	29
230	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2017, 135, e1054-e1091.	1.6	417
231	Selecting heart failure patients for metabolic interventions. Expert Review of Molecular Diagnostics, 2017, 17, 141-152.	3.1	5
232	Follow-up care by a genetic counsellor for relatives at risk for cardiomyopathies is cost-saving and well-appreciated: a randomised comparison. European Journal of Human Genetics, 2017, 25, 169-175.	2.8	8
233	Vitamin D supplementation in heart failure: case closed?. European Heart Journal, 2017, 38, 2287-2289.	2.2	10
234	Exercise and heart failure: Improve your functional status and your biomarker profile. European Journal of Preventive Cardiology, 2017, 24, 1358-1359.	1.8	6

#	ARTICLE	IF	CITATIONS
235	Macrophages take centre stage in the heartâ€˜brainâ€˜kidney axis. Nature Reviews Nephrology, 2017, 13, 388-390.	9.6	8
236	Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. European Heart Journal, 2017, 38, 2034-2041.	2.2	66
237	New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations. Expert Opinion on Pharmacotherapy, 2017, 18, 645-655.	1.8	12
238	Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	3.7	164
239	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 92-98.	4.1	129
240	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	7.1	115
241	New Blood Pressureâ€˜Associated Loci Identified in Meta-Analyses of 475â€˜000 Individuals. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	48
242	Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72Âˆh in an Experimental Rat Model of Acute Myocardial Infarction. Journal of Cardiovascular Translational Research, 2017, 10, 460-469.	2.4	7
243	Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Value in Health, 2017, 20, 1260-1269.	0.3	32
244	From Inflammation to Fibrosisâ€˜Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities. Current Heart Failure Reports, 2017, 14, 235-250.	3.3	222
245	Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. Cardiovascular Pathology, 2017, 30, 23-26.	1.6	17
246	Plasma Proenkephalin and Poor Long-Term Outcome in Renal Transplant Recipients. Transplantation Direct, 2017, 3, e190.	1.6	12
247	Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. Science Translational Medicine, 2017, 9, .	12.4	36
248	Awareness of atrial fibrogenesis and natriuretic peptide release. Netherlands Heart Journal, 2017, 25, 225-226.	0.8	0
249	Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. European Journal of Heart Failure, 2017, 19, 512-521.	7.1	127
250	Variability of biomarkers in patients with chronic heart failure and healthy controls. European Journal of Heart Failure, 2017, 19, 357-365.	7.1	102
251	The LifeLines Cohort Study: Prevalence and treatment of cardiovascular disease and risk factors. International Journal of Cardiology, 2017, 228, 495-500.	1.7	79
252	Plasma potassium, diuretic use and risk of developing chronic kidney disease in a predominantly White population. PLoS ONE, 2017, 12, e0174686.	2.5	14

#	ARTICLE	IF	CITATIONS
253	Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure. PLoS ONE, 2017, 12, e0177242.	2.5	25
254	Signature of circulating <scp>microRNAs</scp> in patients with acute heart failure. European Journal of Heart Failure, 2016, 18, 414-423.	7.1	162
255	Ischaemia in heart failure with preserved ejection fraction; is it important?. European Journal of Heart Failure, 2016, 18, 577-578.	7.1	5
256	In EXOG-depleted cardiomyocytes cell death is marked by a decreased mitochondrial reserve capacity of the electron transport chain. BioEssays, 2016, 38, S136-45.	2.5	5
257	Serial galectin-3 and future cardiovascular disease in the general population. Heart, 2016, 102, 1134-1141.	2.9	42
258	Parental vitamin D deficiency during pregnancy is associated with increased blood pressure in offspring via<i>Pax1</i>hypermethylation. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1459-H1469.	3.2	37
259	Biomarkers in heart failure with preserved ejection fraction. Netherlands Heart Journal, 2016, 24, 252-258.	0.8	37
260	Determinants of temporal changes in galectin-3 level in the general population: Data of PREVENT. International Journal of Cardiology, 2016, 222, 385-390.	1.7	10
261	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes and Endocrinology,the, 2016, 4, 840-849.	11.4	159
262	Serum free thiols in chronic heart failure. Pharmacological Research, 2016, 111, 452-458.	7.1	58
263	Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population-based cohort study. ESC Heart Failure, 2016, 3, 189-197.	3.1	25
264	In EXOG-depleted cardiomyocytes cell death is marked by a decreased mitochondrial reserve capacity of the electron transport chain. Inside the Cell, 2016, 1, 134-143.	0.4	0
265	Low potassium excretion but not high sodium excretion is associated with increased risk of developing chronic kidney disease. Kidney International, 2016, 90, 888-896.	5.2	72
266	A translational viewpoint explaining its potential salutary effects. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 257-257.	3.0	1
267	52 Genetic Loci Influencing MyocardialÂMass. Journal of the American College of Cardiology, 2016, 68, 1435-1448.	2.8	113
268	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nature Genetics, 2016, 48, 1151-1161.	21.4	261
269	Galectin-3, Cardiac Function, and Fibrosis. American Journal of Pathology, 2016, 186, 2232-2234.	3.8	15
270	Biomarkers to identify and prevent new-onset heart failure in the community. European Journal of Heart Failure, 2016, 18, 1351-1352.	7.1	3

#	ARTICLE	IF	CITATIONS
271	High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. <i>European Journal of Heart Failure</i> , 2016, 18, 814-821.	7.1	13
272	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2016, 18, 1096-1105.	7.1	160
273	Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. <i>Histopathology</i> , 2016, 69, 542-550.	2.9	46
274	Twenty-eight genetic loci associated with ST-T-wave amplitudes of the electrocardiogram. <i>Human Molecular Genetics</i> , 2016, 25, 2093-2103.	2.9	24
275	Hypertrophy induced KIF5B controls mitochondrial localization and function in neonatal rat cardiomyocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 97, 70-81.	1.9	15
276	Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development. <i>Cardiovascular Research</i> , 2016, 111, 217-226.	3.8	24
277	Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes—a translational viewpoint explaining its potential salutary effects. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 244-255.	3.0	38
278	Predicting Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	227
279	Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. <i>Clinica Chimica Acta</i> , 2016, 452, 50-57.	1.1	33
280	Urinary potassium excretion and risk of cardiovascular events. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 1204-1212.	4.7	29
281	Emerging role of liver X receptors in cardiac pathophysiology and heart failure. <i>Basic Research in Cardiology</i> , 2016, 111, 3.	5.9	54
282	The fibrosis-cell death axis in heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 199-211.	3.9	214
283	Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. <i>Netherlands Heart Journal</i> , 2016, 24, 287-295.	0.8	39
284	LXR± improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 634-643.	6.3	33
285	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 564-569.	1.7	35
286	Inhibition of Interleukin-6 Receptor in a Murine Model of Myocardial Ischemia-Reperfusion. <i>PLoS ONE</i> , 2016, 11, e0167195.	2.5	39
287	ST2 and Galectin-3: Ready for Prime Time?. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2016, 27, 238-52.	0.7	18
288	Obesity-induced chronic inflammation in high fat diet challenged C57BL/6J mice is associated with acceleration of age-dependent renal amyloidosis. <i>Scientific Reports</i> , 2015, 5, 16474.	3.3	62

#	ARTICLE	IF	CITATIONS
289	Cardiac <scp>LXR</scp> Ì± protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Molecular Medicine, 2015, 7, 1229-1243.	6.9	58
290	Biomarkers and low risk in heart failure. Data from <scp>COACH</scp> and <scp>TRIUMPH</scp>. European Journal of Heart Failure, 2015, 17, 1271-1282.	7.1	55
291	The Prognostic Value of Plasma Galectin-3 in Chronic Heart Failure Patients Is Maintained when Treated with Mineralocorticoid Receptor Antagonists. PLoS ONE, 2015, 10, e0119160.	2.5	18
292	The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial. BMJ Open Diabetes Research and Care, 2015, 3, e000090.	2.8	23
293	Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. American Journal of Physiology - Renal Physiology, 2015, 308, F500-F509.	2.7	42
294	ACE inhibition attenuates radiation-induced cardiopulmonary damage. Radiotherapy and Oncology, 2015, 114, 96-103.	0.6	97
295	Vitamin D supplementation and testosterone concentrations in male human subjects. Clinical Endocrinology, 2015, 83, 105-110.	2.4	56
296	Galectin-3, Renal Function, and Clinical Outcomes. Journal of the American Society of Nephrology: JASN, 2015, 26, 2213-2221.	6.1	111
297	Galectin-3 and post-myocardial infarction cardiac remodeling. European Journal of Pharmacology, 2015, 763, 115-121.	3.5	63
298	Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal, 2015, 36, 2565-2573.	2.2	274
299	The liver X receptor agonist <scp>AZ876</scp> protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. European Journal of Heart Failure, 2015, 17, 273-282.	7.1	30
300	State of the Art: Newer biomarkers in heart failure. European Journal of Heart Failure, 2015, 17, 559-569.	7.1	151
301	Low levels of vitamin D are associated with multimorbidity: Results from the LifeLines Cohort Study. Annals of Medicine, 2015, 47, 474-481.	3.8	31
302	Liver X receptor activation enhances CVB3 viral replication during myocarditis by stimulating lipogenesis. Cardiovascular Research, 2015, 107, 78-88.	3.8	13
303	Hemoglobin levels and new-onset heart failure in the community. American Heart Journal, 2015, 169, 94-101.e2.	2.7	18
304	Galectin-3 and heart failure: Prognosis, prediction & clinical utility. Clinica Chimica Acta, 2015, 443, 48-56.	1.1	56
305	Loss of mitochondrial exo/endonuclease EXOG affects mitochondrial respiration and induces ROS-mediated cardiomyocyte hypertrophy. American Journal of Physiology - Cell Physiology, 2015, 308, C155-C163.	4.6	19
306	An Investigation of CYP2D6 Genotype and Response to Metoprolol CR/XL During Dose Titration in Patients With Heart Failure: A MERIT-HF Substudy. Clinical Pharmacology and Therapeutics, 2014, 95, 321-330.	4.7	38

#	ARTICLE	IF	CITATIONS
307	Renal Handling of Galectin-3 in the General Population, Chronic Heart Failure, and Hemodialysis. Journal of the American Heart Association, 2014, 3, e000962.	3.7	46
308	Clinical utility gene card for: arrhythmogenic right ventricular cardiomyopathy (ARVC). European Journal of Human Genetics, 2014, 22, 293-293.	2.8	27
309	The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure. Expert Review of Molecular Diagnostics, 2014, 14, 257-266.	3.1	33
310	Genetic Determinants of P Wave Duration and PR Segment. Circulation: Cardiovascular Genetics, 2014, 7, 475-481.	5.1	45
311	The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the Controlled ROSuvastatin multiNAtional trial in heart failure (CORONA). BMC Medical Genetics, 2014, 15, 140.	2.1	9
312	Effect of Metformin on Left Ventricular Function After Acute Myocardial Infarction in Patients Without Diabetes. JAMA - Journal of the American Medical Association, 2014, 311, 1526.	7.4	136
313	Clinical evaluation of heart failure patients: what good are biomarkers bringing us?. Netherlands Heart Journal, 2014, 22, 113-114.	0.8	0
314	Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 457-462.	3.9	60
315	Gene-Age Interactions in Blood Pressure Regulation: A Large-Scale Investigation with the CHARGE, Global BPgen, and ICBP Consortia. American Journal of Human Genetics, 2014, 95, 24-38.	6.2	109
316	Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH) Tj ETQq0 0 0 rgBTj/Overlock 10 Tf 50 3	1.6	61
317	Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort. Circulation: Heart Failure, 2014, 7, 723-731.	3.9	74
318	Galectin-3: A Modifiable Risk Factor in Heart Failure. Cardiovascular Drugs and Therapy, 2014, 28, 237-246.	2.6	63
319	Galectin 3: Newest Marker of HF Outcomes. Current Emergency and Hospital Medicine Reports, 2014, 2, 112.	1.5	3
320	Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. Lancet Diabetes and Endocrinology,the, 2014, 2, 719-729.	11.4	319
321	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nature Genetics, 2014, 46, 826-836.	21.4	281
322	Urinary Potassium Excretion and Risk of Developing Hypertension. Hypertension, 2014, 64, 769-776.	2.7	68
323	Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. American Heart Journal, 2014, 167, 853-860.e4.	2.7	128
324	Biomarkers for Risk Prediction in Acute Decompensated Heart Failure. Current Heart Failure Reports, 2014, 11, 246-259.	3.3	16

#	ARTICLE	IF	CITATIONS
325	Outcome in Phospholamban R14del Carriers. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 455-465.	5.1	146
326	Cardiac Function and Architecture Are Maintained in a Model of Cardioresstricted Overexpression of the Prorenin-Renin Receptor. <i>PLoS ONE</i> , 2014, 9, e89929.	2.5	12
327	Abstract 19908: 5-oxoprolinase: a Novel Cardiac Mediator of the Oxidative Stress Response in the Failing Heart. <i>Circulation</i> , 2014, 130, .	1.6	0
328	Galectin-3 in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2013, 15, 1095-1101.	7.1	90
329	Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis. <i>Circulation: Heart Failure</i> , 2013, 6, 107-117.	3.9	371
330	Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 67-75.	2.4	312
331	Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2013, 102, 103-110.	3.3	171
332	The WAP Four-Disulfide Core Domain Protein HE4: A Novel Biomarker for Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 164-169.	4.1	40
333	Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. <i>Nature Genetics</i> , 2013, 45, 621-631.	21.4	282
334	Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVENT. <i>European Heart Journal</i> , 2013, 34, 1424-1431.	2.2	451
335	AKIP1, a Cardiac Hypertrophy Induced Protein that Stimulates Cardiomyocyte Growth via the Akt Pathway. <i>International Journal of Molecular Sciences</i> , 2013, 14, 21378-21393.	4.1	17
336	Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 219-226.	3.9	179
337	Galectin-3: a new biomarker for heart failure progression and prognosis. <i>Laboratoriums Medizin</i> , 2013, 37, 251-260.	0.6	1
338	Gaseous Hydrogen Sulfide Protects against Myocardial Ischemia-Reperfusion Injury in Mice Partially Independent from Hypometabolism. <i>PLoS ONE</i> , 2013, 8, e63291.	2.5	51
339	Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 409-412.	1.7	22
340	Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models. <i>Physiological Genomics</i> , 2012, 44, 443-454.	2.3	42
341	Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. <i>European Journal of Heart Failure</i> , 2012, 14, 1199-1207.	7.1	369
342	Galectin-3 Mediated Cardiovascular Fibrogenesis: An Important Cause of Heart Failure and Cardiovascular Mortality. <i>ACS Symposium Series</i> , 2012, , 397-407.	0.5	2

#	ARTICLE	IF	CITATIONS
343	Metformin in non-Diabetic Patients Presenting with ST Elevation Myocardial Infarction: Rationale and Design of the Glycometabolic Intervention as Adjunct to Primary Percutaneous Intervention in ST Elevation Myocardial Infarction (GIPS)-III Trial. Cardiovascular Drugs and Therapy, 2012, 26, 417-426.	2.6	41
344	The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. Journal of Steroid Biochemistry and Molecular Biology, 2012, 132, 282-289.	2.5	71
345	<i>DHRS7C</i> , a novel cardiomyocyte-expressed gene that is down-regulated by adrenergic stimulation and in heart failure. European Journal of Heart Failure, 2012, 14, 5-13.	7.1	24
346	Plasma renin and outcome in the community: data from PREVEND. European Heart Journal, 2012, 33, 2351-2359.	2.2	28
347	Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population. Heart, 2012, 98, 1348-1353.	2.9	27
348	A Genome-Wide Association Study of Circulating Galectin-3. PLoS ONE, 2012, 7, e47385.	2.5	41
349	New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Failure Reviews, 2012, 17, 191-201.	3.9	64
350	The fibrosis marker galectin-3 and outcome in the general population. Journal of Internal Medicine, 2012, 272, 55-64.	6.0	303
351	Regulation of the (pro)renin-renin receptor in cardiac remodelling. Journal of Cellular and Molecular Medicine, 2012, 16, 722-729.	3.6	23
352	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine, 2011, 43, 60-68.	3.8	506
353	Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin. Journal of Molecular Medicine, 2011, 89, 377-387.	3.9	21
354	Vitamin D and cardiovascular disease: a jack of all trades?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 123-124.	1.7	4
355	Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H459-H468.	3.2	144
356	Galectin-3 in Cardiac Remodeling and Heart Failure. Current Heart Failure Reports, 2010, 7, 1-8.	3.3	192
357	Influence of Diabetes Mellitus and Hyperglycemia on Prognosis in Patients ≥ 70 Years Old With Heart Failure and Effects of Nebivolol (Data from the Study of Effects of Nebivolol Intervention on) Tj ETQq1 1 0.784314 \log_{10} /Overlock 10 TF Cardiology, 2010, 106, 78-86.e1.	1.56	34
358	Telomere length and outcome in heart failure. Annals of Medicine, 2010, 42, 36-44.	3.8	37
359	Bone marrow dysfunction in chronic heart failure patients. European Journal of Heart Failure, 2010, 12, 676-684.	7.1	86
360	The effects of the PPAR- γ agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus. Journal of Human Hypertension, 2010, 24, 74-76.	2.2	9

#	ARTICLE	IF	CITATIONS
361	Galectin-3: a novel mediator of heart failure development and progression. European Journal of Heart Failure, 2009, 11, 811-817.	7.1	434
362	Universal risk factors for multifactorial diseases. European Journal of Epidemiology, 2008, 23, 67-74.	5.7	301
363	Nebivolol: third-generation β^2 -blockade. Expert Opinion on Pharmacotherapy, 2007, 8, 1539-1550.	1.8	32
364	Genetics in Heart Failure: Where Are We Headed?. Congestive Heart Failure, 2006, 12, 329-334.	2.0	4
365	Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. Journal of Molecular Medicine, 2004, 82, 678-687.	3.9	55
366	Increased expression of cardiac angiotensin II type 1 (AT) receptors decreases myocardial microvessel density after experimental myocardial infarction. Cardiovascular Research, 2003, 57, 434-442.	3.8	52
367	The Imbalance Between Oxygen Demand and Supply as a Potential Mechanism in the Pathophysiology of Heart Failure: The Role of Microvascular Growth and Abnormalities. Microcirculation, 2003, 10, 113-126.	1.8	98
368	Early expression of natriuretic peptides and SERCA in mild heart failure. International Journal of Cardiology, 2001, 78, 5-12.	1.7	29